Bioethics, Law and European Integration: Christian Byk
Bioethics, Law and European Integration: Christian Byk
Bioethics, Law and European Integration: Christian Byk
4 ~ 2011
UDK 174:34
Conference paper
Christian Byk*
ABSTRACT
* Correspondence address: Judge at the Court of Appeal, Paris; Secretary general - International Association of
Law**, Ethics and Science, 19 rue Carpeaux, 75018 Paris France. e:mail: christian.byk@aliceadsl.fr
** The Association constitutes an international and multidisciplinary network in the field of science, ethics and
society (www.iales.org ). It has been publishing the International Journal of Bioethics (www.eska.fr ), a bilingual
quarterly, since 1990 .
431
JAHR~Vol. 2~No. 4~2011
When looking back to the recent history of Bioethics and Law in Europe, we see the
emergence of mechanisms to produce new norms outside the medical and scientific
community. What is interpreted as the end of a paternalistic ethical system, also
common to the bioethics movement in the USA, is also the symbol that law is
viewed in Europe as an appropriate way to bring bioethics issues at the forefront of
a societal debate.
The counterpart of this "political" appropriation of Bioethics – in the traditional
meaning that it has become a question for citizens’ discussion- is the fact that the
law might be perceived as imposing a new "paternalistic" approach, not the one of
the medical ethics but the one of the State imposing to individuals rules based on a
collective idea of good, happiness or of what is a normal social behaviour.
432
Christian Byk: Bioethics, law and European integration
law reform commission, they all add in mind the issue: should we legislate?
Even the new National Bioethics Committees which were set up as standing
committees with a mandate to organise ethics discussion very early raised the
same question and were influential in suggesting to governments and parlia-
ments to move to legislation while their opinions also served as references in
court disputes.
Therefore parliamentary committees reorganised themselves to tackle with
bioethical issues: special commissions were set up; offices for technology as-
sessment were incited to deal with such issues.
• The second category gathers bodies which are part of the regulating process
adopted to rule specific biomedical technologies. Some do it on a broad scale
at the national level such as the Human Fertilisation and Embryology authori-
ty in the UK or the Biomedicine Agency in France. Others do it on case by
case review: IRBs for research on human beings or transplant or genetic thera-
py committees…Both produce bylaws or "case law" according to their man-
date. They merely interpret or apply the existing legislation more than they
create it but they have anyway a very concrete role for those who are either
practising the technologies concerned or applying to benefit from them.
Whatever is the ethical issue concerned, a clinical case, a biomedical protocol or a
broader societal issue; there is today at least one body to look at it. Public ethical
institutions have clearly replaced professional associations at the forefront of the bi-
oethics debate. This change in dealing with bioethical issues raised another impor-
tant feature: the capacity of the mandated institutions to work democratically. For
that, they have to be inspired by the legal practice and develop a due process of law
in the specific area of bioethical issues.
433
JAHR~Vol. 2~No. 4~2011
process of law?
It certainly means that contradictory arguments have to be identified and dis-
cussed, that the process of elaborating an opinion should be transparent and
that the opinion should be argued.
Regarding the agencies in charge with the regulation of technologies and prac-
tices, how can we be sure that they do not re-create a closed world for experts
that will leave outside lay persons and public representation? How can we be
sure that their decision will not be biased by conflict of interests?
A more sensitive question would be
• How can we prevent the review of research protocols or individual clinical
cases by ethics bodies giving birth to an "ethicocracy"? Transparency, rational
reasoning and possibility to appeal are necessary as a counterpart of the au-
thoritative role of those new bodies in making decisions. Efforts have been
made in different European countries to improve this process but this is too
often a task which is the consequence of major dysfunctions of the system.
We may say that the XXI century marks the triumph of bioethics institutions be-
cause we now have five categories of such institutions in Europe: national bioethics
committees, ethics research committees, high technology ethics committees (on ge-
netics, organ transplant, biotechnology…), clinical (or hospital) ethics committees
and academic or professional ethics committees. At least, the first 3 categories are
usually regulated by law. But, we do not have yet a global perception of what is the
result of this integration of bioethics institutions in law policy making. Does it real-
ly lead to more democracy in the field of biomedicine and biotechnology or are we
entering into a "Brave new world"?
434
Christian Byk: Bioethics, law and European integration
issues that concern the individual rights of the patients as well as some societal
choices, bioethics and biolaw however keep their eyes wide open on the practice.
They try to be references for existing practices in suggesting and sometimes impos-
ing limits and conditions to health care providers and patients. Globally, they offer a
set of norms to rule the different techniques and to make them socially acceptable
rather than to challenge the legitimacy of such techniques.
In doing so, bioethics and biolaw may be viewed as derived products from biology
rather than sub branches of ethics and law. In supplying the traditional medical eth-
ics, which most patients criticized for its paternalist attitude and which many physi-
cians thought it was no more in capacity to bring appropriate answers to the ethical
legal and social issues generated by the reproductive and genetic revolutions, biolaw
developed a practical and concrete approach to facilitate the access to the new tech-
niques in the respect of individual rights. But it did not really challenge the philoso-
phy and organisation of the techno-scientific society.
It therefore contributed and reinforced some of the main characteristics of our post-
modern society: individualism and subjectivity, on the one hand; materialism, con-
sumerism and reification of the human body, on the other hand.
For this reasons, opponents to this positivist approach think that it is not enough to
introduce some ethical questioning to the way we produce our law. They argue
about the necessity to substantiate our legislation on strong fundamental values
rather than on bioethical discussion and procedural norms.
435
JAHR~Vol. 2~No. 4~2011
In other cases, the process is working the other way around as with the principles of
privacy and non discrimination which have been broadly applied in the field of ge-
netics and access to health services.
But, the idea and practice of establishing a set of fundamental rights may be confus-
ing.
It might mean that the benefactors of such rights are entitled to claim the applica-
tion of the rights in the different areas of biomedicine and that those rights are uni-
versal, authorise limited exceptions and may serve as references to develop derived
principles.
The fundamental rights approach could also be a way to introduce in the legal sys-
tem the idea that the rights designed as fundamental are at the top level of a new
hierarchy of norms, no more grounded on a formal distinction but essentially based
on their substance.
Due to the fact that they contribute to define what is human, one of the main char-
acteristics of such rights is their transcendence which means that they surpass all
other rights and principles. They offer some objective definition of the "human na-
ture" and find references in the concept of jus naturalism and also in religious belief.
We may therefore fear that they will reintroduce some form of dogmatism and ab-
solutism in our law. The controversy rose by the utility and applications of the con-
cept of dignity but also the ongoing discussion about embryo research are good il-
lustrations of such risk.
Although the consequence of this ethico-legal approach is well known in US Bio-
ethics, it might be more influential in Europe because in most countries biomedical
research and its applications are largely relying on a State and Society support. Law
therefore plays in Europe an important role in implementing the different national
policies in the field of life sciences.
As some of these policies are restrictive while other are more permissive, there is in
Europe a specific geography for Biolaw which differs considerably from the US tra-
ditional distinction between federal regulation (only binding for the researchers ask-
ing for federal funds) and State law which may be unexistent in many areas of bio-
ethics. Consequently harmonising legislation in Europe is the only way to make the
idea that fundamental values could rule biomedical issues without infringing upon
individual human rights acceptable.
436
Christian Byk: Bioethics, law and European integration
437
JAHR~Vol. 2~No. 4~2011
marriage between social values and reality that constitutes the legitimacy of the Eu-
ropean legal system.
438
Christian Byk: Bioethics, law and European integration
What they require from the health care providers is more and more the satisfaction
of their personal desire and happiness than it is a therapeutic treatment.
Therefore, the pursuit of further knowledge by the physician on the one hand and
the pursuit of happiness by the individual on the other hand could progressively
transform the physician-patient relationship on a purely legal convention losing its
specific characteristic which implies a mutual respect of each partner.
• Such a consequence has probably already occurred in circumstances when
business is prevailing over medical considerations:
We could certainly ask why so many physicians are interested in industrial
countries to develop new reproductive technologies, the financial cost of
which is high. But we all know what a couple could do to get a desired child.
We are sometimes surprised to hear of the existence of very modern genetic
centres providing with genetic medicine a few people in countries where gen-
eral hospitals cannot usually face their normal duties.
New technologies are also a good way of advertising the ability in medicine or
simply the ambition to be viewed as a person who is at the forefront of the
new medicine.
Sometimes these events are good successes: it was the case with Prof. Chris
Barnard’s first heart transplant or with the birth of Louise Brown due to B.
Edwards & A. Steptoe, but this is not always the case so it is the reason why it
appeared necessary to include an ethical approach to the European regulatory
policy.
It largely concerns the ethical review of biomedical research. Since 1991 the
European Union Biomedical Research Program has included specific research
incentives for bioethical issues related to medical research.
It also covers the assessment and the regulation of a wider range of bioethical
problems at the European level.
After having set up two ad hoc committees (on embryo research and human ge-
nome research) the European Union instituted in 1991 a standing group (on
ethics of biotechnology) to advise the Commission on ethical aspects of Euro-
pean regulations draft.
The other European organization, the Council of Europe, which is an inter-
governmental institution for cooperation, has had such a standing body since
1983: this is the now called the steering committee on bioethics (CDBI),
which prepared many recommendations (on genetic issues, reproductive tech-
nologies, human experimentation...), the European convention on biomedi-
cine and human rights and is presently pursuing its mission to elaborate pro-
tocols to the European convention on bioethics.
439
JAHR~Vol. 2~No. 4~2011
440
Christian Byk: Bioethics, law and European integration
Regarding what is properly called the European regulations; only a few texts are spe-
cifically referring to ethical issues: we can quote the 1989 directive on blood prod-
ucts which mentions the ethical rules adopted by the Council of Europe and the
2001 directive on clinical trials which mentions the role of ethics review commit-
tees. But for many, the 1989 regulation was not deemed as being very efficient be-
cause the ethical rules were mentioned as an objective to fulfil with and not as an
obligation to compel with.
Another text, a draft, attempted to include ethical considerations. It concerned the
issue of patenting biotechnology but as these considerations did not appear to make
ethical issues as prominent, the European Parliament rejected the bill. The new one
which was introduced in 1996 and adopted in 1998 was more explicit about ethical
issues, especially the prohibition to patent the human body and its components and
to ban germ line gene therapy.
Indeed, the recent history of these European regulations proves how illusory it could
be trying to incorporate different preoccupations in the same text. It could mean
that the enforcement of Human Rights provisions in the field of biomedical scienc-
es should probably follow a different process of harmonisation.
441
JAHR~Vol. 2~No. 4~2011
The concept of filiations also plays an important role in contributing to the identifi-
cation of each man as a single person having his/her own biological and social ori-
gins.
Since it is an individual physical integrity and an individual private life which are
primarily at stake, the Human Rights are in a prominent position, and particularly
articles 2 (right to life), 3 (right to be protected against treatment contrary to hu-
man dignity), 8 (right to privacy), 12 (right to marriage) and 14 (right not to be
discriminated) of the European Convention.
However, the way these principles can be implemented and enforced in the bio-
medical field is not so simple because of the divergences existing in national legisla-
tions or practices as we mentioned above. So, there is a need for a process which al-
lows some European harmonisation. It could be done in two ways: the jurisprudence
of the European Court of Human Rights and the elaboration of new Human Rights
instruments.
442
Christian Byk: Bioethics, law and European integration
443
JAHR~Vol. 2~No. 4~2011
stantial issues - although conflicts of views are still existing and important - it
raises more difficulties when the question of a following up procedure is rais-
ing. In fact, the Members States rejected the idea to have the Court of Human
Rights as direct judiciary recourse but they also refused to create any ad hoc
body to follow the implementation of the Convention. But as the convention
is binding for member States, it may be used as a reference in court to support
the recognition of new rights and to solve individual cases.
Conclusion
444